Business Context and Reporting Period
Company: InnovAge Holding Corp. (INNV)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended September 30, 2025 (Fiscal Q1 2026)
Business Overview: InnovAge is the largest Program of All-Inclusive Care for the Elderly (PACE) provider in the U.S., serving approximately 7,890 participants across 20 centers in California, Colorado, Florida, New Mexico, Pennsylvania, and Virginia. The company operates on a fully capitated model, bearing 100% of the financial risk for participant healthcare costs.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 (Sep 30, 2025) | Q1 2025 (Sep 30, 2024) |
|---|---|---|
| Total Revenues | $236,105 | $205,142 |
| Operating Income | $8,289 | $(4,896) |
| Net Income (GAAP) | $7,669 | $(5,710) |
| Net Income Attributable to InnovAge | $8,019 | $(4,929) |
| EPS (Diluted) | $0.06 | $(0.04) |
| Adjusted EBITDA (Non-GAAP) | $17,642 | $6,476 |
| Center-Level Contribution Margin | $51,356 | $34,541 |
| Cash and Cash Equivalents | $67,146 | $39,032 (End of Period Q1 2025) |
| Total Debt Outstanding | $60,082 | $60,000 |
Liquidity: As of September 30, 2025, the company held $67.1 million in cash and cash equivalents and $42.3 million in short-term investments. The Revolving Credit Facility has $85.4 million of remaining capacity.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 15.1% year-over-year to $236.1 million, driven by a 9.9% increase in member months and a 4.7% increase in capitation rates.
- Profitability Turnaround: The company reported a net income of $7.7 million compared to a net loss of $5.7 million in the prior year. Operating income improved from a loss of $4.9 million to a profit of $8.3 million.
- Cost Dynamics:
- External Provider Costs: Increased 1.5% to $108.9 million. Cost per participant decreased 7.6% due to lower nursing facility utilization and higher pharmacy rebates, offsetting a 9.9% increase in member months.
- Cost of Care: Increased 19.7% to $75.9 million, primarily due to higher headcount, wage rates, and costs associated with transitioning to in-house pharmacy services.
- Debt Restructuring: On August 8, 2025, the company amended its Credit Agreement, refinancing the Term Loan Facility to $50.7 million and extending the maturity date to August 8, 2028.
- Asset Sale: The company closed the sale of its managing member interest in InnovAge Senior Housing Thornton (SH1) and adjacent land on September 11, 2025, recording a $0.1 million loss on assets held for sale.
Outlook, Risks, and Management Commentary
- Regulatory Environment: Management highlights the impact of the "One Big Beautiful Bill Act" (OBBBA) adopted in July 2025, which mandates significant reductions in federal Medicaid spending and introduces new work requirements. This may lead to decreased enrollment and downward pressure on capitation rates.
- Government Shutdown: A partial federal government shutdown effective October 1, 2025, may cause delays in government agency operations, though no direct financial impact has been realized to date.
- Expansion Challenges: The California Department of Health Care Services (DHCS) has suspended attestations for planned de novo centers in Downey and Bakersfield pending remediation of deficiencies identified in the Sacramento and San Bernardino centers.
- Labor Market: Continued workforce shortages in geriatrics and direct care roles are driving wage inflation and retention challenges.
- Legal Proceedings:
- Stockholder Settlement: A $27.0 million settlement regarding a securities class action was preliminarily approved in June 2025, with a final hearing scheduled for December 5, 2025. The company has accrued $10.1 million for its share.
- Investigations: The company is cooperating with civil investigative demands from the DOJ and Colorado Attorney General regarding billing and enrollment practices. Losses cannot be estimated at this time.
Investor Verification Checklist
- Medicaid Policy Impact: Verify the specific state-level implementation of the OBBBA and its potential effect on PACE capitation rates and enrollment eligibility.
- California Expansion Status: Monitor the timeline for remediation of the Sacramento and San Bernardino centers to determine when de novo center openings in Downey and Bakersfield can proceed.
- Legal Settlement Finalization: Confirm the final approval of the $27.0 million securities class action settlement and any potential additional liabilities from ongoing DOJ investigations.
- Pharmacy Transition Costs: Assess the long-term cost savings from the in-house pharmacy transition against the current increase in "Cost of Care" expenses.
- Debt Covenants: Review compliance with the amended Credit Agreement covenants, specifically the secured net leverage ratio, given the refinancing in August 2025.